Ревматологические маски ВИЧ-инфекции. Часть 2. Мультисистемные поражения

Вторая часть лекции посвящена вопросам дифференциальной диагностики отдельных иммуновоспалительных ревматических заболеваний и синдромов, связанных непосредственно с ВИЧ-инфекцией, с акцентом на синдром восстановления иммунитета на фоне антиретровирусной терапии, дифференциальную диагностику синдрома Шегрена и диффузного интерстициального лимфоцитарного синдрома, манифестацию системной красной волчанки при ВИЧ-инфекции. Рассмотрены современная классификация поражения мышц и вопросы патогенеза васкулита у ВИЧ-инфицированных пациентов.

1. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May; 224(4648):500-3. doi: 10.1126/science.6200936.

2. Гриднева ГИ, Белов БС. Актуальные вопросы ведения пациентов с ВИЧ-инфекцией и ревматическими заболеваниями. Современная ревматология. 2021;15(6):7-12. doi: 10.14412/1996-7012-2021-6-7-12.

3. Zhang X, Li H, Li T, et al. Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol. 2007 Aug;34(8):1760-4.

4. Christoforidou A, Galanopoulos N. Diffuse connective tissue disorders in HIV-infected patients. Mediterr J Rheumatol. 2018 Sep;29(3): 148-55. doi:10.31138/mjr.29.3.148.

5. Кравченко АВ, Юрин ОГ, Беляева ВВ, Покровский ВВ. Лечение инфекции, вызываемой вирусом иммунодефицита человека в Российской Федерации. Терапевтический архив. 2009;81(4):64-8.

6. Marquez J, Restrepo CS, Candia L, et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol. 2004 Apr;31(4):741-6.

7. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum. 2005 Dec;35(3):166-74. doi:10.1016/j.semarthrit.2005.03.007.

8. Yang JJ, Tsai MS, Sun HY, et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. J Microbiol Immunol Infect. 2015 Apr; 48(2):130-6. doi: 10.1016/j.jmii.2013.08.002.

9. Боева ЕВ, Беляков НА. Синдром восстановления иммунитета. Инфекция и иммунитет. 2018;8(2):139-49.

10. Cherif I, Tsevi YM, Bawe LD, et al. Efficacy of highly active antiretroviral therapy alone in the treatment of diffuse lymphocytic infiltration syndrome in an ivorian patient living with HIV: a case report. Med Trop Sante Int. 2021 Aug 20; 1(3):mtsibulletin.2021.118. doi: 10.48327/mtsibulletin.2021.118.

11. Oksenhendler E, Autran B, Gorochov G, et al. CD8 lymphocytosis and pseudotumoral splenomegaly in HIV infection. Lancet. 1992 Jul; 340(8813):207-8. doi: 10.1016/0140-6736(92)90471-e.

12. Pedaprolu AS, Jajoo S, Mahakalkar C, et al. Navigating Parotid Lymphoepithelial Cysts in HIV Patients: A Tale of Two Distinct Scenarios. Cureus. 2023 Dec;15(12): e50399. doi:10.7759/cureus.50399.

13. Tripathi AK, Gupta N, Ahmad R, et al. HIV disease presenting as parotid lymphoepithelial cysts: a presumptive diagnosis of diffuse infiltrative lymphocytic syndrome (DILS). J Assoc Physicians India. 2004 Nov;52:921-3.

14. Ghrenassia E, Martis N, Boyer J, et al. The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun. 2015 May;59:19-25. doi: 10.1016/j.jaut.2015.01.010.

15. Vargas PA, Mauad T, Böhm GM, et al. Parotid gland involvement in advanced AIDS. Oral Dis. 2003 Mar;9(2):55-61. doi: 10.1034/j.1601-0825.2003.02868.x.

16. Liao Y, Li YJ, Hu XW, et al. Benign lymphoepithelial cyst of parotid gland without human immunodeficiency virus infection: A case report. World J Clin Cases. 2023 Feb;11(4):931-7. doi:10.12998/wjcc.v11.i4.931.

17. Sekikawa Y, Hongo I. HIV-associated benign lymphoepithelial cysts of the parotid glands confirmed by HIV-1 p24 antigen immunostaining. BMJ Case Rep. 2017 Sep;2017: bcr2017221869. doi:10.1136/bcr-2017-221869.

18. Mandel L, Hong J. HIV-associated parotid lymphoepithelial cysts. J Am Dent Assoc. 1999 Apr;130(4):528-32. doi:10.14219/jada.archive.1999.0247

19. Joshi J, Shah S, Agarwal D, Khasgiwal A. Benign lymphoepithelial cyst of parotid gland: Review and case report. J Oral Maxillofac Pathol. 2018 Jan;22:91-7. doi:10.4103/jomfp.JOMFP_252_17.

20. Shanti RM, Aziz SR. HIV-associated salivary gland disease. Oral Maxillofac Surg Clin North Am. 2009 Aug;21(3):339-43. doi:10.1016/j.coms.2009.04.002.

21. Кувардин ЕС, Григорьева ИН, Бехтерева ИА и др. Клеточный состав воспалительных инфильтратов малой слюнной железы как дополнительный диагностический критерий первичного синдрома Шегрена. Научно-практическая ревматология. 2021; 59(4):434-41.

22. Хван ЮИ, Торгашина АВ. Эволюция международных классификационных критериев синдрома Шегрена. Научно-практическая ревматология. 2023;61(6):650-7.

23. Blokland SLM, Hillen MR, Kruize AA, et al. Increased CCL25 and T helper cells expressing CCR9 in the salivar glands of patients with primary Sjögren’s syndrome: potential new axis in lymphoid neogenesis. Arthritis Rheumatol. 2017 Oct;69(10):2038-51. doi: 10.1002/art.40182.

24. Yang JJ, Tsai MS, Sun HY, et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. J Microbiol Immunol Infect. 2015 Apr; 48(2):130-6. doi: 10.1016/j.jmii.2013.08.002.

25. Каневская МЗ. Ревматологические синдромы при ВИЧ-инфекции. Клиническая медицина. 2014;92(12):12-9.

26. McArthur CP, Africa CW, Castellani WJ, et al. Salivary gland disease in HIV/AIDS and primary Sjögren's syndrome: analysis of collagen I distribution and histopathology in American and African patients. J Oral Pathol Med. 2003 Oct;32(9):544-51. doi: 10.1034/j.1600-0714.2003.00159.x.

27. Saigal R, Chakraborty A, Yadav RN, Goyal LK. Rheumatological Manifestations in HIV-Positive Patients: A Single-Center Study. Adv Ther. 2020 Oct;37(10):4336-45. doi: 10.1007/s12325-020-01470-3.

28. Насонов ЕЛ. Системная красная волчанка. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 113.

29. Akram B, Khan M, Humphrey MB. HIVAssociated Rheumatic Diseases: A Narrative Review. J Clin Rheumatol. 2024 Mar;30(2):e42e45. doi: 10.1097/RHU.0000000000002028.

30. Lebrun D, Hentzien M, Cuzin L, et al. Epidemiology of autoimmune and in ammatory diseases in a French nationwide HIV cohort. AIDS. 2017 Sep;31(15):2159-66. doi: 10.1097/QAD.0000000000001603.

31. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002 Dec;1(6):329-37. doi:10.1016/s1568-9972(02)00086-1.

32. Nevinsky GA. Immune Response and Production of Abzymes in Patients with Autoimmune and Neurodegenerative Diseases. Biochemistry (Mosc). 2025 Jan;90:373-400. doi: 10.1134/S0006297924604167.

33. Iordache L, Bengoufa D, Taulera O, et al. Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era. Medicine (Baltimore). 2017 Mar;96(10):e6230. doi:10.1097/MD.0000000000006230.

34. Steve RJ, Alex D, Yesudhason BL, et al. Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It. Curr HIV Res. 2021;19(3):277-85. doi:10.2174/1570162X19666210217120337.

35. Тлиш ММ, Наатыж ЖЮ, Кузнецова ТГ, Городин ВН. Особенности дерматологической патологии на фоне ВИЧ-инфекции. Терапевтический архив. 2019;91(11):10-4.

36. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol. 2009 Jul;21(4):404-10. doi:10.1097/BOR.0b013e32832c9d04.

37. Kawakita C, Kinomura M, Otaka N, et al. HIV-associated Immune Complex Kidney Disease with C3-dominant Deposition Induced by HIV Infection after Treatment of IgA Nephropathy. Intern Med. 2019 Oct;58(20):3001-7. doi:10.2169/internalmedicine.2439-18.

38. Naovarat BS, Reveille JD, Salazar GA, et al. Systemic lupus erythematosus in the setting of HIV-1 infection: a longitudinal analysis. Clin Rheumatol. 2020 Feb;39(2):413-8. doi:10.1007/s10067-019-04867-w.

39. Торгашина АВ, Соловьев СК. Особенности Т-регуляторных клеток у больных системной краснои волчанкой. Современная ревматология. 2018;12(4):9-15. doi: 10.14412/1996-7012-2018-4-9-15.

40. Liao HY, Tao CM, Su J. Concomitant systemic lupus erythematosus and HIV infection: A rare case report and literature review. Medicine (Baltimore). 2017 Dec;96(51):e9337. doi: 10.1097/MD.0000000000009337.

41. O'Kelly B, McNally C, McConkey S, Durcan L. HIV and systemic lupus erythematosus: where immunodeficiency meets autoimmunity. Lupus. 2020 Aug;29(9):1130-2. doi:10.1177/0961203320934851.

42. Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve. 2005 Sep;32(3):247-60. doi: 10.1002/mus.20338.

43. Nelke C, Kleefeld F, Preusse C, et al. Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathol Commun. 2022 Jun;10(1):84. doi: 10.1186/s40478-022-01389-6.

44. Zell SC, Nielsen S. Clinical correlates to muscle biopsy findings in HIV patients experiencing fatigue: a case series. J Int Assoc Physicians AIDS Care (Chic). 2002 Summer;1(3): 90-4. doi:10.1177/154510970200100303.

45. Carroll MB, Holmes R. Dermatomyositis and HIV infection: case report and review of the literature. Rheumatol Int. 2011 May;31(5):673-9. doi:10.1007/s00296-009-1231-x.

46. Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017 Apr;88(15):1454-60. doi:10.1212/WNL.0000000000003821.

47. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol. 1988 Feb;23(2):168-73. doi:10.1002/ana.410230210.

48. Grady BPX, Nanlohy NM, van Baarle D. HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection. Immun Ageing. 2016 Mar;13:10. doi:10.1186/s12979-016-0065-0.

49. Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017 Feb;81:227-39. doi: 10.1002/ana.248471.

50. Hedberg-Oldfors C, Lindgren U, Basu S, et al. Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing. Brain Pathol. 2021 May;31(3):e12931. doi:10.1111/bpa.12931.

51. Nogalska A, D’Agostino C, Cacciottolo M, et al. Abnormalities of mitophagy in sporadic inclusion-body myositis (s-IBM) muscle fibers. Neurology. 2014;82(10):P3.288. doi:10.1212/WNL.82.10_supplement.P3.288.

52. Lindgren U, Roos S, Hedberg Oldfors C, et al. Mitochondrial pathology in inclusion body myositis. Neuromuscul Disord. 2015; 25(4):281-8. doi:10.1016/j.nmd.2014.12.010.

53. Gardner K, Hall PA, Chinnery PF, Payne BAI. HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies. Toxicol Pathol. 2014 Jul;42(5):811-22. doi:10.1177/0192623313503519.

54. Nelke C, Dziewas R, Minnerup J, et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine. 2019 Nov;49:381-8. doi: 10.1016/j.ebiom.2019.10.034.

55. Vega LE, Espinoza LR. Vasculitides in HIV Infection. Curr Rheumatol Rep. 2020 Aug;22(10): 60. doi:10.1007/s11926-020-00945-0.

56. Vornicu A, Obri c B, Sorohan B, et al. ANCA-associated vasculitis in a HIV-infected patient:a case-based review. BMC Nephrol. 2023 Jul;24(1):210. doi:10.1186/s12882-023-03244-9.

57. De Paoli MC, Moretti D, Scolari Pasinato CM, Buncuga MG. Henoch-Schцnlein purpura in a cocaine consumer man with HIV infection and ANCA-p positivity. Medicina (B Aires). 2016;76(4):245-8.

58. Monteiro EJ, Caron D, Balda CA, et al. Anti-glomerular basement membrane glomerulonephritis in an HIV positive patient: case report. Braz J Infect Dis. 2006 Feb;10(1):55-8. doi:10.1590/s1413-86702006000100011.

59. Гриднева ГИ, Белов БС, Аронова ЕС. ВИЧ-инфекция и аутоиммунные болезни: современное состояние проблемы. ВИЧинфекция и иммуносупрессии. 2025; 17(1):7-18.